Blue Water Vaccines (BWV) Reports Q1 Net Loss of $2.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
May 13, 2022 5:01 PM EDTClosed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate developments, including additional data for universal influenza candidate, BWV-101, identifying additional epitopes of limited variability for H3N2 and influenza B strains$18.6 million in Cash as of March 31, 2022
CINCINNATI, May 13, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company), today announced its financial results for the first quarter ended March 31, 2022 and provided... More
